中文摘要：

靶向巨噬細胞抑制受體高質量，如信號調(diào)節(jié)蛋白α (SIRPα)新的動力，在癌癥治療中是一條有前景的途徑機製性梗阻。盡管SIRPα的配體CD47在腫瘤細胞上廣泛表達組建，但其在所有正常細胞上的同時存在引發(fā)了對毒性和療效的擔憂進一步。本研究確定CD200R1更多的合作機會，它與特定類型腫瘤和有限正常細胞上的CD200結合延伸，作為吞噬作用的替代抑制檢查點。阻斷或去除巨噬細胞中的CD200R1或腫瘤細胞中的CD200服務好，可以增加吞噬作用并抑制腫瘤生長新趨勢。在人類中，CD200R1主要在免疫抑制性巨噬細胞中表達共謀發展，并由白細胞介素-4誘導學習。與利用酪氨酸磷酸酶Src同源2域磷酸酶(SHP)-1和SHP-2的SIRPα不同，CD200R1通過激酶Csk介導其抑制作用聽得懂。結合CD200R1-CD200和SIRPα-CD47的阻斷應用優勢，進一步增強了吞噬作用，并減少CD200表達腫瘤的生長，相比于單獨的阻斷高效節能。因此影響力範圍，靶向CD200R1-CD200是巨噬細胞中免疫檢查點阻斷的有前景策略，可以單獨進行新創新即將到來，也可以與其他檢查點的阻斷結合不合理波動。

英文摘要：

Targeting macrophage inhibitory receptors like signal regulatory protein α (SIRPα) is a promising avenue in cancer treatment. Whereas the ligand of SIRPα, CD47, is widely expressed on tumor cells, its simultaneous presence on all normal cells raises concerns about toxicity and efficacy. This study identifies CD200R1, which binds CD200 on specific tumor types and limited normal cells, as an alternative inhibitory checkpoint for phagocytosis. Blocking or removing CD200R1 from macrophages or CD200 from tumor cells increases phagocytosis and suppresses tumor growth. In humans, CD200R1 is mainly expressed in immunosuppressive macrophages and is induced by interleukin-4. Unlike SIRPα that utilizes phosphatases Src homology 2 domain phosphatase (SHP)?1 and SHP-2, CD200R1 mediates its inhibitory effect via the kinase Csk. Combined CD200R1-CD200 and SIRPα-CD47 blockade further boosts phagocytosis and reduces tumor growth of CD200-expressing tumors, compared to either blockade alone. Thus, targeting CD200R1-CD200 is a promising strategy for immune checkpoint blockade in macrophages, either alone or alongside blockade of other checkpoints.

論文信息：

論文題目：D200R1-CD200 checkpoint inhibits phagocytosis differently from SIRPα-CD47 to suppress tumor growth

期刊名稱：Nature Communications

時間期卷：16, Article number: 5145 (2025)

在線時間：2025年6月3日

DOI：doi.org/10.1038/s41467-025-60456-3

產(chǎn)品信息：

貨號：CP-005-005

規(guī)格：5ml+5ml

品牌：Liposoma

產(chǎn)地：荷蘭

名稱：Clodronate Liposomes and Control Liposomes

辦事處：Target Technology（靶點科技）

注射方式：靜脈注射

劑量和頻率：100ul/次，建模前1次重要工具，隔3天積極拓展新的領域，一共注射4次。腫瘤模型性能。

氯膦酸鹽二鈉脂質(zhì)體清除單核巨噬細胞多種方式，在腫瘤模型中單核巨噬細胞功能研究，荷蘭Liposoma巨噬細胞清除劑Clodronate Liposomes見刊于Nature Communications：CD200R1-CD200 免疫檢查點以不同于 SIRPα-CD47 的方式抑制吞噬作用技術創新，從而抑制腫瘤生長

Liposoma巨噬細胞清除劑Clodronate Liposomes氯膦酸二鈉脂質(zhì)體的材料和方法：

In vivo mouse tumor models

Tumor injections and treatments: For WEHI-231 and A20, pools of three clones of Tac+ GFP+ cells (1?×?106 each) were injected intravenously (WEHI-231) or subcutaneously (A20) in 6-10-week-old Rag1?/? mice. Alternatively, for WEHI-231, a polyclonal population of luciferase+ Tac+ GFP+ WEHI-231 cells (1?×?106) was used. At the indicated times after tumor cell injection, mice received intraperitoneal injections every 2 days of Tac mAb 7G7 or Ctrl mAb (200?µg), along with either CD200 mAb OX-90 (200?µg), SIRPα mAb 27 (200?μg), both mAbs, or Ctrl mAb 2A3 (200?µg). For macrophages depletion in vivo, mice were injected I.V. with 100?μl of clodronate liposomes or control liposomes (Liposoma BV, Amsterdam, Netherlands) every 4 days, starting from 1 day prior to tumor transplantation and until the end of the experiment.